VRDN-006 / Viridian Therap - LARVOL DELTA

Recent Business Highlights (Businesswire) - "VRDN-008: phase 1 healthy volunteer data expected in 2H 2026: VRDN-008 phase 1 clinical trial in healthy volunteers is ongoing....VRDN-006: development plan on track for disclosure in 2026."

P1 data • Pipeline update • Immunology

VRDN-006 (Businesswire) - "Viridian anticipates sharing development plans for VRDN-006 in 2026."

Pipeline update • Immunology

VRDN‑006: Phase 1 proof‑of‑concept IgG reduction; 2026 development plan update (Businesswire) - "In a phase 1 clinical trial in healthy volunteers, VRDN-006 showed IgG reductions consistent with the FcRn inhibitor class, spared albumin and LDL, and was generally well-tolerated. Viridian anticipates communicating development plans in 2026."

Clinical • P1 data • Immunology

VRDN-006 Showed IgG Reduction Proof-of-Concept in Healthy Volunteers. (FinancialContent) - "VRDN-006 showed IgG reductions in its ongoing phase 1 clinical trial consistent with the FcRn inhibitor class. VRDN-006 was sparing of albumin and LDL and was generally well-tolerated, with no dose-limiting toxicities or serious adverse events."

P1 data • Immunology

Viridian Therapeutics Highlights 2025 Corporate Priorities... (Businesswire) - "Viridian submitted an IND for VRDN-006 in December 2024 and, upon clearance, anticipates initiating a phase 1 clinical trial in healthy volunteers in early 2025...Viridian expects data from the phase 1 clinical trial in Q3 2025, including proof-of-concept IgG reductions in healthy volunteers."

New P1 trial • P1 data • Immunology